{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009780","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.433581+00:00","generated_at":"2026-05-15T09:03:29.587301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SeaStar Medical Q4 2025 revenue $420K; net loss narrows to $2.9M; cash grows to $12M","bullets":["Net revenue Q4 2025 $420K (vs $67K Q4 2024); full year $1.2M (vs $135K).","Net loss Q4 2025 $2.9M ($0.80/share) vs $4.4M ($8.98/share) Q4 2024; cash $12.0M (up from $1.8M).","QUELIMMUNE expanded to 16 children's hospitals; SAVE Registry enrollment completed (50 patients).","NEUTRALIZE-AKI trial >50% enrolled (181/339); modular PMA submission for adult AKI initiated.","Guides 2026 net product revenue ~$2M; plans to add 15 more hospital sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009780","json":"https://secwatch.observer/filing/0001437749-26-009780.json","markdown":"https://secwatch.observer/filing/0001437749-26-009780.md","text":"https://secwatch.observer/filing/0001437749-26-009780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000143774926009780/0001437749-26-009780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000143774926009780/icu20260313_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:03:29.587301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}